SCA
ARRY

Secor Capital Advisors’s Array Biopharma Inc ARRY Stock Holding History

Secor Capital Advisors’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-60,305
Closed -$254K – 809
2015
Q4 		$254K Buy
+60,305
New +$275K 0.07% 422

Other funds holding ARRY

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Secor Capital Advisors's ARRY Position: Q1 2016 in Review

Secor Capital Advisors sold out of Array Biopharma Inc (ARRY) in Q1 2016, closing a stake of 60,305 shares — an estimated $254K sold.

Secor Capital Advisors first reported a position in ARRY in Q4 2015 and held it in 1 quarter. The position peaked at $254K in Q4 2015. 132 funds tracked by Wall St. Rank hold ARRY as of Q1 2016.

  • Secor Capital Advisors reported no remaining Array Biopharma Inc position as of Q1 2016 after selling out during the quarter.
  • Secor Capital Advisors sold 60,305 Array Biopharma Inc shares in Q1 2016, an estimated $254K.
  • Secor Capital Advisors first reported a position in Array Biopharma Inc in Q4 2015 and held it in 1 quarter.
  • Secor Capital Advisors's Array Biopharma Inc position peaked at $254K in Q4 2015.
  • 132 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q1 2016.

Based on Secor Capital Advisors's 13F filing for Q1 2016, filed 10 May 2016.